Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

Strategies for biopharma in integrating agentic AI—to achieve incremental gains in efficiency, while delivering meaningful ...

Superluminal partners with Eli Lilly to develop AI-driven small molecule therapies targeting GPCRs for obesity and ...

The report details the administration’s potential plans for a variety of issues that will directly impact pharma.

The statement appears to be a response to the President’s recent publication of letters to 17 pharma companies about reducing ...

Strategies for biopharma in integrating agentic AI—to achieve incremental gains in efficiency, while delivering meaningful progress in how data insights inform commercial decision-making.